HF
NRIX icon

HRT Financial’s Nurix Therapeutics NRIX Stock Holding History

HRT Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,020
Closed -$92K – 3757
2025
Q3 		$92K Buy
+10,020
New +$104K ﹤0.01% 2537
2024
Q1 		– Sell
-86,269
Closed -$890K – 2835
2023
Q4 		$890K Buy
+86,269
New +$591K 0.01% 1048
2023
Q3 		– Sell
-28,432
Closed -$284K – 2867
2023
Q2 		$284K Buy
+28,432
New +$290K ﹤0.01% 1658

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's NRIX Position: Q4 2025 in Review

HRT Financial sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 10,020 shares — an estimated $92K sold.

HRT Financial first reported a position in NRIX in Q2 2023 and held it in 3 quarters. The position peaked at $890K in Q4 2023. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • HRT Financial reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 10,020 Nurix Therapeutics shares in Q4 2025, an estimated $92K.
  • HRT Financial first reported a position in Nurix Therapeutics in Q2 2023 and held it in 3 quarters.
  • HRT Financial's Nurix Therapeutics position peaked at $890K in Q4 2023.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.